Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer

BackgroundOvarian cancer (OC) is amongst the most lethal of common cancers in women. Lacking in specific symptoms in the early stages, OC is predominantly diagnosed late when the disease has undergone metastatic spread and chemotherapy is relied on to prolong life. Platinum-based therapies are prefe...

Full description

Bibliographic Details
Main Authors: David Howard, David James, Jezabel Garcia-Parra, Belen Pan-Castillo, Jenny Worthington, Nicole Williams, Zoe Coombes, Sophie Colleen Rees, Kerryn Lutchman-Singh, Lewis W. Francis, Paul Rees, Lavinia Margarit, R. Steven Conlan, Deyarina Gonzalez
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
ovarian cancer
resistance
cyclin dependent kinase inhibitor
dinaciclib
cisplatin
platinum
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1014280/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1014280/full

Similar Items